Lancet:氯胺酮用于老年术后谵妄预防效果不显著

2017-06-01 zhangfan MedSci原创

单一的亚麻醉剂量氯胺酮不能改善老年患者手术后谵妄

谵妄是一种常见且严重的术后并发症。氯胺酮亚麻醉通常用于术后镇痛而且有证据表明氯胺酮可预防谵妄。近日研究人员评估了氯胺酮预防老年人术后谵妄的有效性。

在名为PODCAST的多中心随机研究中,研究人员招募60岁以上的全身麻醉下手术患者,随机在麻醉诱导后接受安慰剂、低剂量的氯胺酮(0.5 mg/kg)或高剂量氯胺酮(1.0 mg/kg)。使用混乱评估法在术后第3天评估谵妄。

研究招募患者672人,其中安慰剂组222人,低剂量氯胺酮组227人,高剂量氯胺酮组223人。研究发现氯胺酮对谵妄发生无明显作用 (19·45% vs 19·82%,绝对差异0.36%, 95% CI -6.07 -7.38, p=0.92)。与安慰剂相比,氯胺酮剂量增加导致术后幻觉(P = 0.01)和噩梦(P = 0.03)概率增加。各组之间心血管,肾,传染性,胃肠道以及出血性不良事件无显著差异。

研究认为单一的亚麻醉剂量氯胺酮不能改善老年患者手术后谵妄。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=369345, encodeId=a55736934586, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Tue Jul 09 09:21:52 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828977, encodeId=d07918289e778, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 26 17:17:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273659, encodeId=35a712e36595a, content=<a href='/topic/show?id=35136411609' target=_blank style='color:#2F92EE;'>#氯胺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64116, encryptionId=35136411609, topicName=氯胺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307295, encodeId=8885130e29592, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205614, encodeId=36d420561436, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Jun 02 12:38:06 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205245, encodeId=36252052457a, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jun 01 13:40:45 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2019-07-09 小微940490

    mark

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=369345, encodeId=a55736934586, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Tue Jul 09 09:21:52 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828977, encodeId=d07918289e778, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 26 17:17:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273659, encodeId=35a712e36595a, content=<a href='/topic/show?id=35136411609' target=_blank style='color:#2F92EE;'>#氯胺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64116, encryptionId=35136411609, topicName=氯胺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307295, encodeId=8885130e29592, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205614, encodeId=36d420561436, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Jun 02 12:38:06 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205245, encodeId=36252052457a, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jun 01 13:40:45 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2018-03-26 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=369345, encodeId=a55736934586, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Tue Jul 09 09:21:52 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828977, encodeId=d07918289e778, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 26 17:17:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273659, encodeId=35a712e36595a, content=<a href='/topic/show?id=35136411609' target=_blank style='color:#2F92EE;'>#氯胺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64116, encryptionId=35136411609, topicName=氯胺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307295, encodeId=8885130e29592, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205614, encodeId=36d420561436, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Jun 02 12:38:06 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205245, encodeId=36252052457a, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jun 01 13:40:45 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-03 jml2009
  4. [GetPortalCommentsPageByObjectIdResponse(id=369345, encodeId=a55736934586, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Tue Jul 09 09:21:52 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828977, encodeId=d07918289e778, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 26 17:17:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273659, encodeId=35a712e36595a, content=<a href='/topic/show?id=35136411609' target=_blank style='color:#2F92EE;'>#氯胺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64116, encryptionId=35136411609, topicName=氯胺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307295, encodeId=8885130e29592, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205614, encodeId=36d420561436, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Jun 02 12:38:06 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205245, encodeId=36252052457a, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jun 01 13:40:45 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=369345, encodeId=a55736934586, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Tue Jul 09 09:21:52 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828977, encodeId=d07918289e778, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 26 17:17:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273659, encodeId=35a712e36595a, content=<a href='/topic/show?id=35136411609' target=_blank style='color:#2F92EE;'>#氯胺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64116, encryptionId=35136411609, topicName=氯胺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307295, encodeId=8885130e29592, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205614, encodeId=36d420561436, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Jun 02 12:38:06 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205245, encodeId=36252052457a, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jun 01 13:40:45 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-02 flysky120

    学习一下知识了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=369345, encodeId=a55736934586, content=mark, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=526e2567988, createdName=小微940490, createdTime=Tue Jul 09 09:21:52 CST 2019, time=2019-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828977, encodeId=d07918289e778, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Mon Mar 26 17:17:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273659, encodeId=35a712e36595a, content=<a href='/topic/show?id=35136411609' target=_blank style='color:#2F92EE;'>#氯胺酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64116, encryptionId=35136411609, topicName=氯胺酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04d6114, createdName=jml2009, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307295, encodeId=8885130e29592, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sat Jun 03 04:17:00 CST 2017, time=2017-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205614, encodeId=36d420561436, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Fri Jun 02 12:38:06 CST 2017, time=2017-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=205245, encodeId=36252052457a, content=学习了,涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jun 01 13:40:45 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-06-01 1ddf0692m34(暂无匿称)

    学习了,涨知识

    0

相关资讯

JAMA Intern Med:姑息治疗中,利培酮或氟哌啶醇不能改善谵妄症状

抗精神病药广泛用于谵妄的痛苦症状,但是在安慰剂对照试验中还尚未建立姑息治疗的功效。来自澳大利亚的研究人员开展了一项研究,该研究的目的是确定在接受姑息疗法的患者中,与安慰剂相比,利培酮或氟哌啶醇对于缓解与痛苦相关的谵妄症状的疗效。在2008年8月13日至2014年4月2日期间,研究人员在11家澳大利亚医院或医院姑息治疗服务中进行了双盲,平行臂,剂量滴定随机临床试验,参与者具有生命限制性疾病,谵妄,并

Crit Care Med:酒精戒断与谵妄知多少!

近期,一项发表在杂志Crit Care Med上的研究旨在评估酒精戒断综合征和震颤性谵妄患者发生创伤性损伤的发生率、预测因素和预后。此项研究是回顾性多中心队列研究。在美国三个创伤中心中进行,共招募了2010 - 2014年入院的二十八万一百名创伤患者。主要研究措施包括酒精戒断综合征和震颤性谵妄的发生,损伤特征,酒精戒断综合征的危险因素,临床结果,酒精戒断综合征的药物治疗和酒精临床研究所戒断评估(C

LANCET:术后还在常规使用氯胺酮么?赶紧戳进来看看……

氯胺酮通常用于缓解术后谵妄和疼痛,但一项最新的多中心试验表明,该药在治疗这些症状方面可能没有什么用。

Front Syst Neurosci:降低术中额叶α波功率或可预防高危患者术后谵妄与POCD的发生

每年有超过1600万的美国老人接受全麻手术,而高达40%的患者术后出现谵妄和/或认知功能障碍(POCD)。谵妄和POCD的发生与生活质量下降,提前退休, 1年死亡率增加,和长期的认知能力下降都相关。 因此,许多研究者认为麻醉和手术产生的严重应激对大脑老化产生了明显地影响,患者承受应激的能力不足则会增加谵妄和POCD的发生危险。术前认知功能较低的患者谵妄与POCD的发生风险会增加,但是患者术前

Medicine:尼莫地平可降低全麻下老年患者术后谵妄的发生率

尼莫地平是临床常用的一种钙离子拮抗剂,可降低海马神经元凋亡率以降低术后认知功能障碍的发生率(POCD)。本研究旨在评价尼莫地平对老年人全麻术后谵妄的影响。 研究共纳入了60名全麻下接受脊柱外科手术的患者,采用随机数字表将其随机分为2组:对照组(C组 )和尼莫地平组(N组 )。N组,麻醉诱导前注射尼莫地平7.5 μg/(kg×h),持续30分钟 ,C组则给予等容量的生理盐水组。注射前0分钟, 

Anesthesiology:谵妄是否会增加术后死亡风险?

谵妄是一种急性可逆性的老年综合征,表面大脑功能失代偿。 谵妄可能会导致术后不良结局,但是有关谵妄是否是增高死亡率的独立预测因素存在争议。因此,研究人员评估了成人非心脏手术患者术后谵妄和死亡率之间的相关性。使用Cochrane,MEDLINE / PubMed,“护理和联合健康文献累积指数”以及Embase等数据库进行了系统的搜索。两名独立评审员进行了筛选和数据提取。用随机效应模型计算的汇总效应估计